Business News • PR NewsWire • ASCO 2015: Superior overall survival for afatinib compared to erlotinib demonstrated in head-to-head trial in patients with previously treated advanced squamous cell carcinoma of the lung

ASCO 2015: Superior overall survival for afatinib compared to erlotinib demonstrated in head-to-head trial in patients with previously treated advanced squamous cell carcinoma of the lung

ASCO 2015: Superior overall survival for afatinib compared to erlotinib demonstrated in head-to-head trial in patients with previously treated advanced squamous cell carcinoma of the lung

RIDGEFIELD, Conn., May 31, 2015 /PRNewswire/ -- Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced...

View More : http://www.prnewswire.com/news-releases/asco-2015-superior-overall-survival-for-afatinib-compared-to-erlotinib-demonstra...

Releted News by prnewswire

„Belt and Road Initiative" von XCMG startet internationale Servicetour in Xuzhou

David B. Holl Appointed Direct Selling Association Chairman Of The Board

Ibrutinib (IMBRUVICA®) Phase Ib/II Data Show Promise in Patients with Chronic Graft-Versus-Host-Disease

Veeva Systems Expands Healthcare Professional and Organisation Data Offering with Veeva OpenData for France